Can patients with ankylosing spondylitis take upadacitinib?

Patients suffering from ankylosing spondylitis can take upadacitinib to treat the disease. A 14-week study involving 187 patients whose disease was not well controlled with other treatments showed that upapatinib was effective in reducing symptoms of the disease. About 52% of patients who received upadacitinib experienced a reduction in the number and severity of their symptoms, compared with 26% of patients in the placebo group. A study involving about 300 patients with non-radiographic axial spondyloarthritis showed that upapatinib improved symptoms of the disease, with 45 percent of patients taking upadacitin experiencing at least a 40 percent improvement in symptoms after 14 weeks.